- Details
- Piyush Agarwal reflects on a debate at the EAU 2019 where he debated Seth Lerner, MD who is a preeminent urologist in bladder cancer. Dr. Lerner was favoring open surgery and Dr. Agarwal was favoring robotic surgery for the purpose of the debate as he conveys the positioning of the arguments with Charles Ryan. If you look at the robotic literature in urologic cancers, there is no evidence of any o...
|
- Details
- Brant Inman discusses the role of the surgeon in the management of metastatic bladder cancer. Oftentimes surgical management is overlooked in favor of systemic therapies, including chemotherapy and immunotherapy. However, in certain cases, a surgical approach may provide a higher cure rate. Dr. Inman and Dr. Kamat discuss appropriate patient selection and scenarios for surgery and the role of neoa...
|
- Details
- Stephen Williams and his team explored the question, what is the association of patient survival and intensity of treatment with total Medicare costs that are associated with radical cystectomy vs trimodal therapy for older adults with localized muscle-invasive bladder cancer in a time frame of longer than 180-days? He and Alicia Morgans discuss the study, its findings, and implications in patient...
|
- Details
- Ashish Kamat, MD discusses the focus of the International Bladder Cancer Group, discussing the pathway to developing the definition of BCG-unresponsive. Today the unified definition of BCG-unresponsive disease essentially denotes those patients for whom any more BCG is futile. This has opened the door to many ongoing clinical trials. The discussion moves to review these trials, including Nadofarag...
|
- Details
- Neal Shore discusses the current 2019 shortage of BCG with Ashish Kamat and Jonathan Rubenstein. Bacillus Calmette-Guérin (BCG) is used as first-line intravesical therapy following tumor resection of non–muscle-invasive bladder cancer. Bacille Calmette-Guérin (BCG) has been a standard of care for many patients with non-muscle invasive bladder cancer for decades.Merck & Co., Inc., has advised that...
|
- Details
- Josh Meeks and Alicia Morgans discuss the clinical treatment of high-risk NMIBC in a BCG rationed era. Biographies: Josh J. Meeks, MD, PhD, Assistant Professor of Urology and Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine, Chicago Illinois Alicia Morgans, MD, MPH , Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern...
|
- Details
- Sia Daneshmand joins Ashish Kamat in a conversation on the phase III trial comparing blue light flexible cystoscopy with white light flexible cystoscopy for the detection of bladder cancer during surveillance. This study shows significant improvement of the detection of patients with recurrent bladder cancer and for the detection of carcinoma in situ, detecting lesions that are missed with white l...
|
- Details
- Sima Porten speaks about the importance of TURBT and the benefits of enhanced cystoscopy to the patient. She references the new AUA/SUO guidelines recommendation for enhanced cystoscopy and the benefit of Blue Light with Cysview®. Biography: Sima P. Porten, MD, MPH, Assistant Professor, Department of Urology, UCSF Medical Center Related Content: Efficacy and Safety of Blue Light Flexible Cystoscop...
|
- Details
- Badrinath Konety presents Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry. Blue light cystoscopy (BLC) using hexaminolevulinate HCL (Cysview®) has been previously shown to improve the detection of non-muscle-invasive bladder cancer (NMIBC). The objective of this study was to evaluate the detection of malignant lesions in a heterogenou...
|
- Details
- (Length of Discussion: 12 min) Alicia Morgans and Josh Meeks highlight ongoing trials in non-muscle invasive bladder cancer. Reviews of SWOG 1602 and 1605, highlight the great work being done in the search for treatment options for patients with this disease, the ultimate hope for patients is to retain their bladder and potentially be cancer-free. Biographies: Joshua J Meeks, MD, Ph.D., is an Assi...
|
